LIFUP for Treatment of Motor Deficits in Parkinson's Disease
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Oct 13, 2020
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
This trial is a proof-of-concept, proof-of-mechanism study of a novel neuromodulation technology - LIFUP - to treat motor symptoms in PD. Much like Deep Brain Stimulation, LIFUP can be focused on deep brain structures with high spatial accuracy, including those implicated in PD; however, it can do so non-invasively. Other non-invasive neuromodulation tools such as Transcranial Magnetic Stimulation can only target surface brain structures and are not optimal PD treatment tools. This study will test this new technology in 30 participants with PD during simultaneous resting state functional MR...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Diagnosis of Parkinson's disease
- • 2. Age 18-85
- • 3. Fluent in the English language
- Exclusion Criteria:
- • 1. Metal implants that are not MR compatible
- • 2. Neurological diagnosis other than Parkinson's
- • 3. Not fluent in the English language
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Taylor P Kuhn, Ph.D.
Principal Investigator
University of California, Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials